David P. Ng
ORCID: 0000-0001-8604-2073Also affiliated with ARUP Laboratories (United States), ARUP Laboratories (United States)
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Papers
Driven by 2 papers. Top paper: “Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL study (SWOG S1925, NCT#04269902).”.
Anna Moseley, Brian T. Hill, John M. Pagel, Mazyar Shadman, Michael Fisch +9 more
David P. Ng, Luigi Marchionni, Paul D. Simonson, Wikum Dinalankara